Search results

  1. COVID-19 rapid guideline: delivery of radiotherapy (NG162)

    The purpose of this guideline is to maximise the safety of patients who need radiotherapy and make the best use of NHS resources, while protecting staff from infection. It will also enable services to match the capacity for radiotherapy to patient needs if services become limited because of the COVID-19 pandemic.

  2. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (NG158)

    This guideline covers diagnosing and managing venous thromboembolic diseases in adults. It aims to support rapid diagnosis and effective treatment for people who develop deep vein thrombosis (DVT) or pulmonary embolism (PE). It also covers testing for conditions that can make a DVT or PE more likely, such as thrombophilia (a blood clotting disorder) and cancer.

  3. Venous thromboembolism

    Everything NICE has said on assessing, diagnosing, treating and reducing the risk of venous thromboembolism in adults in an interactive flowchart

  4. Suspected cancer recognition and referral

    Everything NICE has said on suspected cancer, recognition and selection for referral or investigation in primary care in an interactive flowchart

  5. Abdominal aortic aneurysm: diagnosis and management (NG156)

    This guideline covers diagnosing and managing abdominal aortic aneurysms. It aims to improve care by helping people who are at risk to get tested, specifying how often to monitor asymptomatic aneurysms, and identifying when aneurysm repair is needed and which procedure will work best.

  6. Aortic aneurysms

    Everything NICE has said on aortic aneurysms in an interactive flowchart

  7. Abdominal aortic aneurysm

    Everything NICE has said on diagnosing and managing abdominal aortic aneurysm in an interactive flowchart

  8. The committee noted that there was no clinical evidence showing that having patiromer improved length or quality of life or allowed patients to stay on optimal doses of renin-angiotensin-aldosterone system (RAAS) inhibitors. It therefore considered that it would be valuable to have studies comparing patiromer plus standard care with standard care alone in people with confirmed hyperkalaemia of 6.0 mmol/litre and above, and that these should investigate: - mortality- disease progression- patterns of RAAS inhibitor use- healthcare utilisation and- health-related quality of life. The committee recalled that the DIAMOND trial is ongoing and may help to provide evidence on mortality (see section 3.11). However, the trial is not going to complete until 2022. The committee concluded that the guidance should be reviewed when evidence from DIAMOND is available.

    Recommendation ID TA623/1 Question The committee noted that there was no clinical evidence showing that having patiromer improved length

  9. Episcissors-60 show promise for mediolateral episiotomy. But there is currently not enough evidence to support the case for routine adoption in the NHS. Research is recommended to address uncertainties about the efficacy and safety of using Episcissors-60. This research should: - determine if using Episcissors-60 in addition to other care bundle measures is more effective in achieving an optimal episiotomy angle and in preventing episiotomy-related obstetric anal sphincter injuries (OASI) than standard episiotomy scissors - include patient-reported outcome measures - address potential equality considerations by ensuring patients at greatest risk of OASI are recruited - determine the relative cost of using Episcissors-60 compared with standard episiotomy scissors.

    Recommendation ID MTG47/1 Question Episcissors-60 show promise for mediolateral episiotomy. But there is currently not enough evidence

  10. Tinnitus: assessment and management (NG155)

    This guideline covers the assessment, investigation and management of tinnitus in primary, community and secondary care. It offers advice to healthcare professionals on supporting people presenting with tinnitus and on when to refer for specialist assessment and management.

  11. Hearing loss

    Everything NICE has said on hearing loss or impairment in adults in an interactive flowchart

  12. Ear, nose and throat conditions

    Everything NICE has said on ear, nose and throat conditions in an interactive flowchart

  13. Tinnitus

    Everything NICE has said on tinnitus in an interactive flowchart.

  14. Drug misuse management in over 16s

    Everything NICE has said on psychosocial interventions and opioid detoxification for drug misuse in an interactive flowchart

  15. Self-harm

    Everything NICE has said on assessing and managing self-harm in an interactive flowchart

  16. Bipolar disorder

    Everything NICE has said on recognising, assessing and managing bipolar disorder in children, young people and adults in an interactive flowchart

  17. Social anxiety disorder

    Everything NICE has said on recognising, assessing and treating social anxiety disorder in children, young people and adults in an interactive flowchart

  18. Headaches

    Everything NICE has said on the most common primary headache disorders in young people aged 12 years and older and adults in an interactive flowchart

  19. Selective internal radiation therapy for unresectable colorectal metastases in the liver (IPG672)

    Evidence-based recommendations on selective internal radiation therapy for unresectable colorectal metastases in the liver in adults. This involves injecting

  20. Varicose veins in the legs

    Everything NICE has said on diagnosing and managing varicose veins in the legs in an interactive flowchart.

  21. Chest pain

    Everything NICE has said on assessing and managing recent suspected cardiac chest pain including acute coronary syndromes and stable angina in an interactive flowchart